Momenta, Baxter deal

Baxter and Momenta said they will partner to co-develop and commercialize two undisclosed biosimilars worldwide. Baxter has the option to add up to four additional biosimilars to the deal. Momenta will receive $33 million up front and is eligible for option payments totaling $28 million if Baxter decides to add additional biosimilars. Momenta could also receive up to $391 million in milestones, plus royalties.

Momenta will be responsible for research and process development costs prior to an IND filing, and Baxter will be responsible for clinical development, manufacturing and commercialization costs. For the four additional biosimilars, Momenta has an option to share up to 30% of the costs and profits. ...